Left atrial appendage occlusion and ligation devices: What is available how to implement them, and how to manage and avoid complications

Current Treatment Options in Cardiovascular Medicine

Volumn 14, Issue 5, 2012, Pages 503-519

  Aryana, Arash ^a   Saad, Eduardo B ^b   D'Avila, André ^c  

^a Regional Cardiology Associates   (United States)

^b HOSPITAL PRÓ CARDÍACO   (Brazil)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Atrial fibrillation; Catheter ablation; Device implant; Left atrial appendage; Ligation; Oral anticoagulation; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CLOPIDOGREL; DABIGATRAN; RIVAROXABAN; WARFARIN;

ARTICLE; BALLOON OCCLUSION; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIAC EQUIPMENT; CARDIOEMBOLIC STROKE; CATHETER ABLATION; COMPARATIVE EFFECTIVENESS; DRUG CONTRAINDICATION; ENDOVASCULAR SURGERY; EQUIPMENT DESIGN; EVIDENCE BASED MEDICINE; GASTROINTESTINAL HEMORRHAGE; GUIDE WIRE; HEART ATRIUM APPENDAGE; HEART ATRIUM FIBRILLATION; HEART ATRIUM THROMBOSIS; HEART SURGERY; HUMAN; LEFT ATRIAL APPENDAGE LIGATION; LEFT ATRIAL APPENDAGE OCCLUSION; OUTCOME ASSESSMENT; PATIENT SAFETY; PATIENT SELECTION; PERCUTANEOUS CORONARY INTERVENTION; PEROPERATIVE COMPLICATION; PROSTHESIS INFECTION; RADIOFREQUENCY ABLATION; RISK FACTOR; RISK REDUCTION; SEPTAL OCCLUDER; SURGICAL ANATOMY; SURGICAL APPROACH; SURGICAL EQUIPMENT; SURGICAL RISK; THROMBOEMBOLISM; THROMBOSIS; TREATMENT PLANNING;

EID: 84870350033     PISSN: 10928464     EISSN: 15343189     Source Type: Journal    
DOI: 10.1007/s11936-012-0203-8     Document Type: Article

References (39)

1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983-8.
2. Whitlock RP, Healey JS, Connolly SJ. Left Atrial Appendage Occlusion Does Not Eliminate the Need for Warfarin. Circulation. 2009;120:1927-32.
3. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006;114:e257-354. (Pubitemid 44252297)
4. Ezekowitz MD, Bridgers SL, James KE, Carliner NH, Colling CL, Gornick CC, Krause-Steinrauf H, Kurtzke JF, Nazarian SM, Radford MJ. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med. 1992;327:1406-12.
5. Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg. 1996;61:755-9. (Pubitemid 26060923)
6. Syed FF, Asirvatham SJ. Left atrial appendage as a target for reducing strokes: Justifiable rationale? Safe and effective approaches? Heart Rhythm. 2011;8:194-8.
7. Johnson WD, Ganjoo AK, Stone CD, Srivyas RC, Howard M. The left atrial appendage: our most lethal human attachment! Surgical implications. Eur J Cardiothorac Surg. 2000;17:718-22. (Pubitemid 30364952)
8. Singh IM, Holmes DR. Left Atrial Appendage Closure. Curr Cardiol Rep. 2010;12:413-21.
9. Al-Saady NM, Obel OA, Camm AJ. Left atrial appendage: structure, function, and role in thromboembolism. Heart. 1999;82:547-54. (Pubitemid 29515446)
10. Manning WJ. Atrial fibrillation, transesophageal echo, electrical cardioversion, and anticoagulation. Clin Cardiol. 1995;18:58. 114.
11. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Kellen JC, Greene HL, Mickel MC, Dalquist JE, Corley SD. Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825-33.
12. Bonow RO, Carabello BA, Chatterjee K, de Leon Jr AC, Faxon DP, Freed MD, Gaasch WH, Lytle BW, Nishimura RA, O'Gara PT, O'Rourke RA, Otto CM, Shah PM, Shanewise JS. Writing Committee Members; American College of Cardiology/American Heart Association Task Force. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2008;118: e523-661.
13. Dawson AG, Asopa S, Dunning J. Should patients undergoing cardiac surgery with atrial fibrillation have left atrial appendage exclusion? Interact Cardiovasc Thorac Surg. 2010;10:306-11.
14. Garcia-Fernandez MA, Perez-David E, Quiles J, et al. Role of left atrial appendage obliteration in stroke reduction in patients with mitral valve prosthesis: a transesophageal echocardiographic study. J Am Coll Cardiol. 2003;42:1253-8.
15. Healey JS,Crystal E, Lamy A, et al. LeftAtrialAppendage Occlusion Study (LAAOS): results of a randomized controlled pilot study of left atrial appendage occlusion during coronary bypass surgery in patients at risk for stroke. Am Heart J. 2005;150:288-93. (Pubitemid 41116255)
16. Katz ES, Tsiamtsiouris T, Applebaum RM, Schwartzbard A, Tunick PA, Kronzon I. Surgical left atrial appendage ligation is frequently incomplete: a transesophageal echocardiographic study. J Am Coll Cardiol. 2000;36:468-71. (Pubitemid 30624009)
17. Blackshear JL, Johnson WD, Odell JA, et al. Thoracoscopic extracardiac obliteration of the left atrial appendage for stroke risk reduction in atrial fibrillation. J Am Coll Cardiol. 2003;42:1249-52. (Pubitemid 37188351)
18. Sievert H, Lesh MD, Trepels T, et al. Percutaneous left atrial appendage transcatheter occlusion to prevent stroke in high-risk patients with atrial fibrillation: Early clinical experience. Circulation. 2002;105:1887-9. (Pubitemid 34437613)
19. Ostermayer SH, Reisman M, Kramer PH, et al. Percutaneous left atrial appendage transcatheter occlusion (PLAATO system) to prevent stroke in high-risk patients with non-rheumatic atrial fibrillation: results from the international multi-center feasibility trials. J Am Coll Cardiol. 2005;46:9-14. (Pubitemid 40905122)
20. Ussia GP, Mule M, Cammalleri V, Scarabelli M, Barbanti M, Imme S, Mangiafico S, Marchese A, Galassi AR, Tamburino C. Percutaneous closure of left atrial appendage to prevent embolic events in high-risk patients with chronic atrial fibrillation. Catheter Cardiovasc Interv. 2009;74:217-22.
21. Park JW, Leithauser B, Gerk U, Vrsansky M, Jung F. Percutaneous left atrial appendage transcatheter occlusion (PLAATO) for stroke prevention in atrial fibrillation: 2-year outcomes. J Invasive Cardiol. 2009;21:446-50.
22. Block PC, Burstein S, Casale PN, et al. Percutaneous left atrial appendage occlusion for patients in atrial fibrillation suboptimal for warfarin therapy: 5-year results of the PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) Study. JACC Cardiovasc Interv. 2009;2:594-600.
23. Chiam PT, Ruiz CE. Percutaneous transcatheter left atrial appendage exclusion in atrial fibrillation. J Invasive Cardiol. 2008;20:E109-13.
24. Sick PB, Schuler G, Hauptmann KE, Grube E, Yakubov S, Turi ZG, Mishkel G, Almany S, Holmes DR. Initial worldwide experience with the WATCHMAN left atrial appendage system for stroke prevention in atrial fibrillation. J Am Coll Cardiol. 2007;49:1490-5. (Pubitemid 46505070)
25. Holmes DR, Reddy VY, Turi ZG, et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet. 2009;374:534-42.
26. Viles-Gonzalez JF, Kar S, Douglas P, Dukkipati S, Feldman T, Horton R, Holmes D, Reddy VY. The clinical impact of incomplete left atrial appendage closure with the Watchman Device in patients with atrial fibrillation: a PROTECT AF (Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients With Atrial Fibrillation) substudy. J Am Coll Cardiol. 2012;59:923-9.
27. Fuller CJ, Reisman M. Stroke Prevention in Atrial Fibrillation: Atrial Appendage Closure. Curr Cardiol Rep. 2011;13:159-66.
28. Bartus K, Bednarek J, Myc J, Kapelak B, Sadowski J, Lelakowski J, Yakubov S, Lee R. Feasibility of closedchest ligation of the left atrial appendage in humans. Heart Rhythm. 2011;8:188-93.
29. Sosa E, Scanavacca M, d'Avila A, Pilleggi F. A new technique to perform epicardial mapping in the electrophysiology laboratory. J Cardiovasc Electrophys. 1996;7:531-6. (Pubitemid 126426338)
30. Bartus K, Bednarek J, Myc J, Kapelak B, Sadowski J, Lelakowski J, Yakubov S, Lee R. Long-term Safety and Efficacy of Percutaneous Left Atrial Appendage Suture Ligation in Patients with Atrial Fibrillation. In press.
31. Harloff A, Handke M, Reinhard M, Geibel A, Hetzel A. Therapeutic strategies after examination by transesophageal echocardiography in 503 patients with ischemic stroke. Stroke. 2006;37:859-64. (Pubitemid 43731922)
32. Bogousslavsky J, Van Melle G, Regli F, Kappenberger L. Pathogenesis of anterior circulation stroke in patients with nonvalvular atrial fibrillation: the Lausanne Stroke Registry. Neurology. 1990;40:1046-50. (Pubitemid 20213969)
33. Miller VT, Rothrock JF, Pearce LA, Feinberg WM, Hart RG, Anderson DC. Ischemic stroke in patients with atrial fibrillation: effect of aspirin according to stroke mechanism. Stroke Prevention in Atrial Fibrillation Investigators. Neurology. 1993;43:32-6. (Pubitemid 23035353)
34. Saad EB, d'Avila A, Costa IP, Aryana A, Slater C, Costa RE, Inácio LA Jr, Maldonado P, Neto DM, Camiletti A, Camanho LE, Polanczyk CA. Very low risk of thromboembolic events in patients undergoing successful catheter ablation of atrial fibrillation with a CHADS2 ≤3: A Long-term Outcome Study. Circ Arrhythm Electrophysiol 2011;4:615-21.
35. Bhargava M, Di Biase L, Mohanty P, Prasad S, Martin DO, Williams-Andrews M, et al. Impact of type of atrial fibrillation and repeat catheter ablation on long-term freedom from atrial fibrillation: results from a multicenter study. Heart Rhythm. 2009;6:1403-12.
36. Oral H, Chugh A, Ozaydin M, Good E, Fortino J, Sankaran S, et al. Risk of thromboembolic events after percutaneous left atrial radiofrequency ablation of atrial fibrillation. Circulation. 2006;114:759-65. (Pubitemid 44268226)
37. Themistoclakis S, Corrado A, Marchlinski FE, Jais P, Zado E, Rossillo A, et al. The risk of thromboembolism and need for oral anticoagulation after successful atrial fibrillation ablation. J Am Coll Cardiol. 2010;55:735-43.
38. Ad N, Henry L, Schlauch K, Holmes SD, Hunt S. The CHADS score role in managing anticoagulation after surgical ablation for atrial fibrillation. Ann Thorac Surg. 2010;90:1257-62.
39. Dagres N, Hindricks G, Kottkamp H, Sommer P, Gaspar T, Bode K, et al. Real-life anticoagulation treatment of atrial fibrillation after catheter ablation: Possible overtreatment of low-risk patients. Thromb Haemost. 2009;102:754-8